7094 Federal Register / Vol. 86, No. 15 / Tuesday, January 26, 2021 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–1218] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘MedicationAssisted Treatment (MAT) for Opioid 

Use Disorder Study’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on August 

28, 2020, to obtain comments from the 

public and affected agencies. CDC 

received two comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Medication-Assisted Treatment 

(MAT) for Opioid Use Disorder Study 

(OMB Control No. 0920–1218, Exp. 02/ 

28/2021)—Revision—National Center 

for Injury Prevention and Control 

(NCIPC), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

CDC seeks a one-year OMB approval 

to continue collecting data for 

Medication-Assisted Treatment (MAT) 

for Opioid use disorder. About 2.4 

million people aged 18 or older have 

opioid use disorders (OUDs) in the 

United States. At any given time, only 

half of these people receive some form 

of treatment, which may include 

medication-assisted treatment (MAT) or 

abstinence-based psychotherapy or selfhelp treatments (i.e., counseling without 

medication [COUN]). The rise in opioid 

overdose deaths, up from 2014–2015 

due partly to a 72% rise in synthetic 

opioid overdose deaths alone, shows 

that engaging and retaining clients in 

OUD treatment is an urgent public 

health need. Only a few studies are 

available to help clients and providers 

make informed decisions about the risks 

and benefits associated with the 

different types of MATs. This 

information is crucial because even 

though each MAT drug helps prevent 

withdrawal symptoms and decreases 

cravings, differences in treatment 

approach and settings influence how 

people respond to the medication and, 

thus, their long-term treatment success. 

The purpose of this study is to 

conduct an epidemiologic, mixedmethods evaluation of OUD treatment in 

real-world outpatient settings. Client 

recruitment for this study was originally 

scheduled to take place between 5/1/ 

2018 and 8/31/2019, however patient 

recruitment levels were lower than 

originally anticipated. The recruitment 

period was extended to 11/30/2019 to 

recruit additional patients. Because the 

follow-up period for this study is 18 

months, patients recruited during the 

extended recruitment period (8/31/2019 

to 11/30/2019) will need to complete 

their final 18-month Patient 

Questionnaire between 2/28/2021 and 

5/31/2021, which is after the current 

OMB expiration date. The extended 

time period is only needed for one of 

the data collections instruments, thus 

there is a reduction in burden of 2,793 

hours. 

The study uses a mixed-method 

approach using quantitative methods 

such as multilevel latent growth models, 

propensity score matching, latent class 

analysis and advance mediation 

analysis and qualitative methods such 

as interactive coding and analysis for 

common themes. There are no costs to 

respondents other than their time. The 

total estimated burden will be 300 

hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Patients ....................... Client Questionnaire 18-month follow-up ........................................... 400 1 45/60 

Federal Register / Vol. 86, No. 15 / Tuesday, January 26, 2021 / Notices 7095 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–01693 Filed 1–25–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–21CG; Docket No. CDC–2021– 

0004] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled A Longitudinal Examination of 

Mental and Physical Health among 

Police Associated with COVID–19. The 

aim of this project is to evaluate the 

longitudinal consequences of the 

COVID–19 pandemic on the mental and 

physical health of police officers. 

DATES: CDC must receive written 

comments on or before March 29, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0004 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

A Longitudinal Examination of 

Mental and Physical Health among 

Police Associated with COVID–19— 

New—National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

Police officers are exposed to several 

stressors during their working lives, 

including traumatic events (e.g., motorvehicle accidents, domestic incidents), 

organizational stressors (e.g., long work 

hours, shiftwork), public criticism, and 

concern about physical harm. On top of 

these day-to-day stressors, the 

coronavirus disease 2019 (COVID–19) 

has contributed to an increase in mental 

and physical risk. Although exact 

figures are not known, in April 2020, it 

was estimated that approximately 17% 

of the New York police department were 

out sick and five officers had died. Over 

1000 police officers had tested positive 

for COVID–19. Since then, rates of 

COVID–19 have not only increased in 

the general population, but also in 

police populations. These preliminary 

studies indicate that police departments 

are under a great deal of stress and at 

greater risk because of COVID–19. Given 

that efficiently performing officers are 

key to successful functioning of law 

enforcement, addressing police mental 

and physical health is imperative for 

their well-being, as well as that of the 

public they serve. Nonetheless, little 

research has been conducted to evaluate 

the physical and mental health 

consequences of the COVID–19 

pandemic on police officers. Thus, 

NIOSH seeks OMB approval to evaluate 

the longitudinal mental and physical 

health effect of the COVID–19 pandemic 

on police officers. 

Previously, in collaboration with 

NIOSH, the University of New York at 

Buffalo (UB) conducted a cross-sectional 

research project to evaluate the mental, 

physical, and subclinical measures of 

health in Buffalo, NY police officers as 

part of the Buffalo Cardio-Metabolic 

Occupational Police Stress (BCOPS) 

study. The BCOPs study itself includes 

a baseline examination and four followup examinations. For this reason, 

NIOSH has mental and physical health 

data on police officers collected prior to 

COVID–19, including stress related 

surveys, blood parameters, physical 

measures, stress biomarkers (cortisol) 

and telomere length data. 

To meet the aims of the current study 

NIOSH has contracted with UB to 

recruit 200 police officers who 

previously participated in a BCOPS 

study. Priority will be placed on 

recruiting officers who participated in 

the last BCOPS study (n=240). If 200 of 

the 240 officers cannot be recruited, 

then UB will try to recruit any officer 

who has previously participated in a 

BCOPS study. A subset of the surveys 

and biological data collected as part of 

the BCOPS studies will be repeated for 

this study. By comparing the responses 

of the surveys and physical data 

collected as part of BCOPS, prior to 

COVID–19, to those obtained during this 

study, NIOSH can evaluate the 

longitudinal physical and psychological